NYU School of Medicine and GSK Collaborate on Promising Target for Pancreatic Cancer

As reported in Langone Health via MedicalXpress, researchers at New York University School of Medicine and GlaxoSmithKline (GSK) are collaborating on an experimental drug that may be effective against a deadly form of pancreatic cancer when used in combination with other immune-boosting therapies. The research results were recently published online in Cancer Cell.

Lead Research/Investigator

George Miller, MD